The national drug regulatory authority has heightened its monitoring of the distribution channels for GLP-1-based weight loss medications. This initiative comes in response to increasing reports of unauthorized sales and misuse.

Coordinated inspections took place at 49 different locations, encompassing online pharmacies, wholesalers, and wellness clinics throughout the country. The primary goal of these actions is to safeguard the supply chain and prevent these specialized drugs from being distributed through illegal means.

Strict Advisory Issued to Pharmaceutical Companies

Recently, the Central Drugs Standard Control Organisation (CDSCO) released a stringent advisory cautioning pharmaceutical firms against promoting prescription weight-loss drugs to the general population. Healthcare professionals have emphasized the importance of adhering to this directive. They assert that it is crucial for all stakeholders in the healthcare sector to comply with these guidelines.

Nationwide Crackdown on Unapproved Fixed Dose Combinations

In a related effort, the Drug Controller General of India (DCGI) commenced a nationwide operation focused on unapproved Fixed Dose Combinations (FDCs). The regulator has called for an assessment of 90 FDCs in their generic names, urging verification of whether approvals have been granted by state or Union Territory drug controllers. These medications include a variety of products such as multivitamins, folic acids, various syrups, and pain relief medications like Paracetamol and Diclofenac Potassium, among others.

Concerns Raised Over Generic GLP-1 Medications

Experts have noted the entry of generic GLP-1 medications into the Indian market at significantly lower prices compared to existing innovator products. Dr. Nikhil Tandon, a professor and head of the Department of Endocrinology and Metabolism at AIIMS, cautioned against the reckless consumption of generic semaglutide. He emphasized that these are potent medications intended for serious health issues, advising the public to exercise caution due to potential side effects.

The Evolving Role of GLP-1 Medications

Dr. Tandon explained that GLP-1 medications were initially developed for diabetes management but later recognized for their efficacy in weight reduction. Another distinguished expert, Dr. V Mohan, a prominent diabetologist, underscored the necessity of rigorous pharmacovigilance. While these medications are generally effective and safe, Dr. Mohan pointed out that adverse effects can occur. He asserted the need for more comprehensive data on their impact in the Indian context.

Call for Qualified Medical Supervision

Furthermore, Dr. Mohan emphasized that these drugs should only be prescribed by qualified healthcare providers. He noted that this approach could improve access for a larger segment of the population while maintaining the quality of care. Both experts advocate for the strict utilization of these medications under the supervision of healthcare professionals, stressing the importance of safety given the potential for significant side effects in certain individuals.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share